Nomura Asset Management’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.25M | Sell |
171,980
-438
| -0.3% | -$19.2K | 0.02% | 476 |
|
|
2025
Q4 | $6.66M | Buy |
172,418
+24,048
| +16% | +$917K | 0.02% | 541 |
|
|
2025
Q3 | $5.23M | Buy |
148,370
+34,728
| +31% | +$1.26M | 0.01% | 584 |
|
|
2025
Q2 | $4.09M | Hold |
113,642
| – | – | 0.01% | 622 |
|
|
2025
Q1 | $3.54M | Buy |
113,642
+12,000
| +12% | +$380K | 0.01% | 641 |
|
|
2024
Q4 | $2.59M | Hold |
101,642
| – | – | 0.01% | 697 |
|
|
2024
Q3 | $2.88M | Hold |
101,642
| – | – | 0.01% | 689 |
|
|
2024
Q2 | $2.68M | Sell |
101,642
-1,120
| -1% | -$31K | 0.01% | 669 |
|
|
2024
Q1 | $3.12M | Sell |
102,762
-19,137
| -16% | -$564K | 0.01% | 645 |
|
|
2023
Q4 | $3.42M | Buy |
121,899
+28,807
| +31% | +$792K | 0.01% | 620 |
|
|
2023
Q3 | $2.53M | Sell |
93,092
-1,760
| -2% | -$52.3K | 0.01% | 659 |
|
|
2023
Q2 | $2.92M | Buy |
94,852
+9,000
| +10% | +$305K | 0.01% | 635 |
|
|
2023
Q1 | $3.09M | Buy |
85,852
+6,003
| +8% | +$223K | 0.02% | 590 |
|
|
2022
Q4 | $3.16M | Buy |
79,849
+1,010
| +1% | +$42.2K | 0.02% | 574 |
|
|
2022
Q3 | $3.17M | Buy |
78,839
+5,000
| +7% | +$214K | 0.02% | 541 |
|
|
2022
Q2 | $3.1M | Buy |
73,839
+5,000
| +7% | +$205K | 0.02% | 590 |
|
|
2022
Q1 | $2.68M | Buy |
68,839
+830
| +1% | +$32.6K | 0.01% | 663 |
|
|
2021
Q4 | $2.71M | Buy |
68,009
+36,810
| +118% | +$1.43M | 0.01% | 672 |
|
|
2021
Q3 | $1.13M | Sell |
31,199
-46,100
| -60% | -$1.79M | 0.01% | 805 |
|
|
2021
Q2 | $3.17M | Sell |
77,299
-65,961
| -46% | -$2.81M | 0.02% | 612 |
|
|
2021
Q1 | $6.25M | Buy |
143,260
+11,060
| +8% | +$524K | 0.04% | 403 |
|
|
2020
Q4 | $6.62M | Buy |
132,200
+30,600
| +30% | +$1.3M | 0.04% | 352 |
|
|
2020
Q3 | $4.28M | Buy |
+101,600
| New | +$4.36M | 0.03% | 418 |
|
Other funds holding RPRX
